Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Strachovsky

Ophthalmology West Islip, NY Medical Doctor

NPI 1003133612 CMS profile 762110

360 Montauk Hwy, West Islip, NY 11795

Open in the dashboard

General payments

$1,507

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Strachovsky of West Islip, NY is reported in the CMS Open Payments database as having received $1,507 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $366 17
2024 General $385 18
2023 General $396 15
2022 General $210 11
2021 General $100 5
2019 General $50 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Strachovsky
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Matthew Strachovsky were reported at $366. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Matthew Strachovsky Ophthalmology median Middle half National median
2019 $50 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $100 $205 $76–$534 $132
2022 $210 $266 $100–$678 $149
2023 $396 $308 $117–$745 $160
2024 $385 $340 $127–$846 $164
2025 $366 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $557 28 payments
  2. Genentech USA, Inc. $253 13 payments
  3. Astellas Pharma US Inc $222 10 payments
  4. Coherus Biosciences Inc. $96 2 payments
  5. Bausch & Lomb Americas Inc. $63 3 payments
  6. Sun Pharmaceutical Industries Inc. $50 2 payments
  7. Glaukos Corporation $49 1 payment
  8. Bausch & Lomb, a division of Bausch Health US, LLC $44 2 payments
  9. Kala Pharmaceuticals, Inc. $36 2 payments
  10. Sandoz Inc. $35 1 payment
  11. Other $101 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,507 69 payments
Products named General payments · program years 2019–2025
  1. EYLEA $281 15 payments
  2. EYLEA HD $276 13 payments
  3. VABYSMO $253 13 payments
  4. Izervay $157 7 payments
  5. Cimerli $131 3 payments
  6. VYZULTA $92 4 payments
  7. Cequa $50 2 payments
  8. BESIVANCE $44 2 payments
  9. INVELTYS $36 2 payments
  10. EYSUVIS $36 2 payments
  11. Other $148 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

156

Median for Ophthalmology: 891

Drug cost

$4,484

Median for Ophthalmology: $68,233

Branded share of claims

19.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brimonidine Tartrate Generic 22 $1,850
Prednisolone Acetate Generic 35 $1,251
Latanoprost Generic 41 $599
Ketorolac Tromethamine Generic 16 $313
Timolol Maleate Generic 11 $176
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 18 $172
Erythromycin Erythromycin Base Brand 13 $124

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$2,074,898

Of which drugs: $1,623,165

Medicare patients

1,027

Average age 78

Services billed

29,587

638 women, 389 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 47%
Ischemic heart disease 42%
Chronic kidney disease 26%
Atrial fibrillation 23%
Heart failure 19%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 123 1,130 $738,295
Injection, faricimab-svoa, 0.1 mg J2777 Office 49 19,740 $537,560
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 19 1,530 $178,946
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 Office 16 351 $66,616
Injection, dexamethasone, intravitreal implant, 0.1 mg J7312 Office 11 175 $28,192
Injection, bevacizumab, 10 mg J9035 Office 20 59 $3,199

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VABYSMO
  • Genentech USA, Inc. $113
$113 — 19,740
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $103
$103 — —
Izervay
  • Astellas Pharma US Inc $73
$73 — —
Cimerli
  • Sandoz Inc. $35
$35 — 351
DEXTENZA
  • Ocular Therapeutix, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record